Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →GSK today announced positive headline results from the B-Well 1 and B-Well 2 phase III trials of bepirovirsen demonstrating statistically significant and…
CTTQ is set to handle importation, distribution, hospital access, and promotional activities while GSK retains the marketing authorization and responsibility…
The agreement grants GSK the ability to review certain early-stage pipeline assets of the SBP Group to evaluate the potential for collaboration opportunities…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
GSK entered an exclusive strategic collaboration on May 11, 2026 with Sino Biopharmaceutical (SBP Group) via its subsidiary Chia Tai Tianqing Pharmaceutical Group (CTTQ) to accelerate the launch of bepirovirsen, a potential first-in-class antisense oligonucleotide for chronic hepatitis B (CHB), in mainland China. Under a supply-and-distribute structure, CTTQ purchases bepirovirsen from GSK under agreed supply terms and handles importation, distribution, hospital access (>5,000 medical centres) and promotional/non-promotional activities, while GSK remains the marketing authorisation holder and retains regulatory, quality, pharmacovigilance and global medical strategy responsibility; GSK is expected to book the sales of bepirovirsen supplied to CTTQ. The initial term is 5.5 years with mutual extension options. The agreement also grants GSK the right to review certain early-stage SBP Group pipeline assets to evaluate collaboration opportunities outside China. Financial terms were not disclosed. Bepirovirsen is under NMPA Priority Review in China and FDA Priority Review (Breakthrough Therapy Designation) in the US with an October 26, 2026 PDUFA target, supported by the Phase 3 B-Well 1/2 functional-cure readouts.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Sino Biopharmaceutical Limited / GSK plc (this deal) | 2026 | — | — |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| bioMerieux SA / BioFire Diagnostics Inc. | 2013 | $485M | 88 |
| Roche Holding AG / Ventana Medical Systems Inc. | 2008 | $3.4B | 88 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2026 deals · Infectious Disease deals